Global Peptide Antibiotics Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are increasing across the globe. A class of antibiotics that are polypeptides which have activity against Gram-negative bacilli, disrupting the cellular membrane are known as Peptide Antibiotics. Some of the examples of this class include actinomycin, bacitracin, colistin, and polymyxin B.
The factors that propel the growth of the Peptide Antibiotics Market include increasing demand, rapid urbanization & industrialization, rise in research & development activities and product development & technological innovations. On the other hand, there are also factors that may hamper the growth of the market such as adverse effects like nephrotoxicity, central & peripheral neurotoxicity, etc.
Peptide Antibiotics Market is classified on the basis of product type, applications, distribution channel and geography. Peptide Antibiotics Market is segmented by product type as Ribosomal Synthesized Peptide Antibiotics and Non-Ribosomally Synthesized Peptide Antibiotics. Peptide Antibiotics Market is classified on applications as commodities, food industry, pharma & healthcare, and others.
Peptide Antibiotics Industry is segmented by distribution channel as online stores, specialty stores and others. Peptide Antibiotics Market is classified on the basis of geography as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa.
The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, Australia & New Zealand. The Middle East and African region consists of GCC, South Africa and North Africa.
By geography, North America is projected to account a major share of the Peptide Antibiotics Market. Some of the key players that fuel the growth of the Peptide Antibiotics Industry include Pfizer, Theravance, Eli Lilly, Savara Pharmaceuticals, Madam Therapeutics, Novartis, Hospira, AMP Therapeutics, Pacgen Life Science Corporation, GlaxoSmithKline, Phosphagenics, Vicuron Pharmaceuticals, Kasten, and others. The key players are focusing on inorganic growth to sustain themselves amidst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Peptide Antibiotics in these regions, from 2012 to 2022 (forecast), covering
• North America
• Southeast Asia
Global Peptide Antibiotics market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Eli Lilly
• Vicuron Pharmaceuticals
• Savara Pharmaceuticals
• AMP Therapeutics
• Madam Therapeutics
• Pacgen Life Science Corporation
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Ribosomal Synthesized Peptide Antibiotics
• Non-Ribosomally Synthesized Peptide Antibiotics
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Peptide Antibiotics for each application, including
• Pharma & Healthcare
• Food Industry
Research Support Specialist, USA